Literature DB >> 16331349

Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells.

C P Muir1, M A Adams, C H Graham.   

Abstract

Compared with monolayer culture, tumour cells cultured as multicellular aggregates (spheroids) exhibit much higher levels of resistance to chemotherapeutic agents, a phenomenon known as multicellular resistance (MCR). Associated with multicellular aggregates is a heterogeneous microenvironment characterised by gradients in oxygen, pH, and nutrients. We previously showed that nitric oxide (NO) signalling plays an important role in the regulation of chemosensitivity in cancer cells cultured as monolayer, and that hypoxia increases resistance to anti-cancer agents largely through a mechanism involving the inhibition of NO signalling. The goal of the present study was to determine whether NO mimetics chemosensitize breast cancer cells in spheroid cultures. Survival of MDA-MB-231 breast carcinoma cells was determined by clonogenic assay following spheroid culture, doxorubicin exposure, and NO mimetic administration. When spheroids were incubated for 24 h with the NO mimetics diethylenetriamine/nitric oxide adduct (DETA/NO) and glyceryl trinitrate (GTN), cell survival after doxorubicin (200 microM) exposure was decreased by 33% (p<0.006) and by up to 47% (p<0.02), respectively. Nitric oxide-mediated signalling involves the generation of the second messenger cyclic guanosine monophosphate (cGMP). Administration of a non-hydrolysable cGMP analogue, 8-Bromo-cGMP, significantly decreased MCR (p<0.04). The effect of NO mimetic exposure on tumour cell chemosensitivity was not due to increased penetration of doxorubicin into spheroids, nor was it associated with an increase in cell proliferation. These results suggest that NO mimetics attenuate MCR to doxorubicin through a mechanism involving cGMP-dependent signalling. Therefore, NO-mimetics may potentially be used as chemosensitizers in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331349     DOI: 10.1007/s10549-005-9076-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Continuously perfused microbubble array for 3D tumor spheroid model.

Authors:  Sivaprakash Agastin; Ut-Binh T Giang; Yue Geng; Lisa A Delouise; Michael R King
Journal:  Biomicrofluidics       Date:  2011-06-03       Impact factor: 2.800

2.  Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.

Authors:  Quanwen Li; Albert B Chow; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

3.  Non-Destructive Tumor Aggregate Morphology and Viability Quantification at Cellular Resolution, During Development and in Response to Drug.

Authors:  Cassandra L Roberge; David M Kingsley; Denzel E Faulkner; Charles J Sloat; Ling Wang; Margarida Barroso; Xavier Intes; David T Corr
Journal:  Acta Biomater       Date:  2020-09-29       Impact factor: 8.947

4.  Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Authors:  Ji-Yeob Choi; William E Barlow; Kathy S Albain; Chi-Chen Hong; Javier G Blanco; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Daniel F Hayes; Christine B Ambrosone
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

5.  A novel self-assembled sandwich nanomedicine for NIR-responsive release of NO.

Authors:  Jing Fan; Nongyue He; Qianjun He; Yi Liu; Ying Ma; Xiao Fu; Yijing Liu; Peng Huang; Xiaoyuan Chen
Journal:  Nanoscale       Date:  2015-11-16       Impact factor: 7.790

6.  Light-Responsive Biodegradable Nanomedicine Overcomes Multidrug Resistance via NO-Enhanced Chemosensitization.

Authors:  Jing Fan; Qianjun He; Yi Liu; Fuwu Zhang; Xiangyu Yang; Zhe Wang; Nan Lu; Wenpei Fan; Lisen Lin; Gang Niu; Nongyue He; Jibin Song; Xiaoyuan Chen
Journal:  ACS Appl Mater Interfaces       Date:  2016-05-27       Impact factor: 9.229

7.  Embedded Spheroids as Models of the Cancer Microenvironment.

Authors:  Kristie M Tevis; Yolonda L Colson; Mark W Grinstaff
Journal:  Adv Biosyst       Date:  2017-08-18

8.  HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.

Authors:  Sophie Doublier; Dimas C Belisario; Manuela Polimeni; Laura Annaratone; Chiara Riganti; Elena Allia; Dario Ghigo; Amalia Bosia; Anna Sapino
Journal:  BMC Cancer       Date:  2012-01-04       Impact factor: 4.430

9.  Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Authors:  Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme; Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-08-27

Review 10.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.